Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In postmenopausal osteoporotics, malabsorption of calcium is associated with reduced levels of serum 1,25-dihydroxyvitamin D. Metabolic studies have shown that calcium absorption can be normalized and calcium balance improved after administration of oral doses of synthetic 1,25-dihydroxyvitamin D3 (Rocaltrol®) 0.25 μg twice daily. Further studies performed at two centers compared the effect of Rocaltrol® 0.25 μg twice daily versus placebo on vertebral fracture rates in osteoporotics. A significant reduction in vertebral fracture rates was seen at the end of 1 year. Those patients who continued on Rocaltrol® for a second and third year showed a progressive decrease in vertebral fractures. Rocaltrol®, administered at a dose of 0.25 μg twice daily, seldom causes hypercalcuria or hypercalcemia in osteoporotic patients on a typical calcium intake of 700 to 800 mg/d. Careful measurements of renal function over a period of 3 years in patients treated with Rocaltrol®, 0.25 μg twice daily, showed no deterioration in renal function. These data suggest that 1,25-dihydroxyvitamin D3 is a useful therapy in the management of patients with postmenopausal osteoporosis, particularly those who have malabsorption of calcium. We found that it improves calcium balance, reduces the vertebral fracture rate, and is safe to use provided that the dietary calcium is monitored and does not exceed 800 mg/d.

Original languageEnglish
Pages (from-to)30-34
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume39
Issue number4 SUPPL. 1
DOIs
StatePublished - 1990

Fingerprint

Calcitriol
Bone Remodeling
Calcium
Kidney
Dietary Calcium
Postmenopausal Osteoporosis
Hypercalcemia
Oral Administration
Placebos
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{4dde65df3786413ca0c3747034e51b34,
title = "Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate",
abstract = "In postmenopausal osteoporotics, malabsorption of calcium is associated with reduced levels of serum 1,25-dihydroxyvitamin D. Metabolic studies have shown that calcium absorption can be normalized and calcium balance improved after administration of oral doses of synthetic 1,25-dihydroxyvitamin D3 (Rocaltrol{\circledR}) 0.25 μg twice daily. Further studies performed at two centers compared the effect of Rocaltrol{\circledR} 0.25 μg twice daily versus placebo on vertebral fracture rates in osteoporotics. A significant reduction in vertebral fracture rates was seen at the end of 1 year. Those patients who continued on Rocaltrol{\circledR} for a second and third year showed a progressive decrease in vertebral fractures. Rocaltrol{\circledR}, administered at a dose of 0.25 μg twice daily, seldom causes hypercalcuria or hypercalcemia in osteoporotic patients on a typical calcium intake of 700 to 800 mg/d. Careful measurements of renal function over a period of 3 years in patients treated with Rocaltrol{\circledR}, 0.25 μg twice daily, showed no deterioration in renal function. These data suggest that 1,25-dihydroxyvitamin D3 is a useful therapy in the management of patients with postmenopausal osteoporosis, particularly those who have malabsorption of calcium. We found that it improves calcium balance, reduces the vertebral fracture rate, and is safe to use provided that the dietary calcium is monitored and does not exceed 800 mg/d.",
author = "Gallagher, {John Christopher G.} and Riggs, {B. L.}",
year = "1990",
doi = "10.1016/0026-0495(90)90269-I",
language = "English",
volume = "39",
pages = "30--34",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate

AU - Gallagher, John Christopher G.

AU - Riggs, B. L.

PY - 1990

Y1 - 1990

N2 - In postmenopausal osteoporotics, malabsorption of calcium is associated with reduced levels of serum 1,25-dihydroxyvitamin D. Metabolic studies have shown that calcium absorption can be normalized and calcium balance improved after administration of oral doses of synthetic 1,25-dihydroxyvitamin D3 (Rocaltrol®) 0.25 μg twice daily. Further studies performed at two centers compared the effect of Rocaltrol® 0.25 μg twice daily versus placebo on vertebral fracture rates in osteoporotics. A significant reduction in vertebral fracture rates was seen at the end of 1 year. Those patients who continued on Rocaltrol® for a second and third year showed a progressive decrease in vertebral fractures. Rocaltrol®, administered at a dose of 0.25 μg twice daily, seldom causes hypercalcuria or hypercalcemia in osteoporotic patients on a typical calcium intake of 700 to 800 mg/d. Careful measurements of renal function over a period of 3 years in patients treated with Rocaltrol®, 0.25 μg twice daily, showed no deterioration in renal function. These data suggest that 1,25-dihydroxyvitamin D3 is a useful therapy in the management of patients with postmenopausal osteoporosis, particularly those who have malabsorption of calcium. We found that it improves calcium balance, reduces the vertebral fracture rate, and is safe to use provided that the dietary calcium is monitored and does not exceed 800 mg/d.

AB - In postmenopausal osteoporotics, malabsorption of calcium is associated with reduced levels of serum 1,25-dihydroxyvitamin D. Metabolic studies have shown that calcium absorption can be normalized and calcium balance improved after administration of oral doses of synthetic 1,25-dihydroxyvitamin D3 (Rocaltrol®) 0.25 μg twice daily. Further studies performed at two centers compared the effect of Rocaltrol® 0.25 μg twice daily versus placebo on vertebral fracture rates in osteoporotics. A significant reduction in vertebral fracture rates was seen at the end of 1 year. Those patients who continued on Rocaltrol® for a second and third year showed a progressive decrease in vertebral fractures. Rocaltrol®, administered at a dose of 0.25 μg twice daily, seldom causes hypercalcuria or hypercalcemia in osteoporotic patients on a typical calcium intake of 700 to 800 mg/d. Careful measurements of renal function over a period of 3 years in patients treated with Rocaltrol®, 0.25 μg twice daily, showed no deterioration in renal function. These data suggest that 1,25-dihydroxyvitamin D3 is a useful therapy in the management of patients with postmenopausal osteoporosis, particularly those who have malabsorption of calcium. We found that it improves calcium balance, reduces the vertebral fracture rate, and is safe to use provided that the dietary calcium is monitored and does not exceed 800 mg/d.

UR - http://www.scopus.com/inward/record.url?scp=0025272220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025272220&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(90)90269-I

DO - 10.1016/0026-0495(90)90269-I

M3 - Article

VL - 39

SP - 30

EP - 34

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4 SUPPL. 1

ER -